Date:5/11/2010

ange GAAP gross profit 30,418 23,319 30% GAAP gross margin 38% 39% Adjustments Share-based compensation 889 591 Amortization of acquired intangible assets 764 764 Non-GAAP gross profit 32,071 24,674 30% Non-GAAP gross margin 40% 42% GAAP operating income 17,435 10,275 70% GAAP operating margin 22% 17% Adjustments Share-based compensation 2,322 1,999 Amortization of acquired intangible assets 764 764 Non-GAAP operating income 20,521 13,038 57% Non-GAAP operating margin 25% 22% GAAP net income 15,517 11,735 32% GAAP net margin 19% 20% Adjustments: Share-based compensation 2,322 1,999 Amortization of acquired intangible assets 764 764 Deferred tax impact related to acquired intangible assets (296) (296) Non-GAAP net income 18,307 14,202 29% Non-GAAP net margin 23% 24% GAAP net income 15,517 11,735 32% Add back: Depreciation and amortization 6,380 5,007 Interest (income) expenses, net (98) 50 Income tax expenses 2,199 1,883 EBITDA 23,998 18,675 29% Adjustments: Share-based compensation
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Related medicine technology :

1. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
2. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
3. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
4. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
5. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
6. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
7. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. Jazz Pharmaceuticals Announces Public Offering of Common Stock
10. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent
11. Somanetics Corporation Announces 24 Clinical Abstracts on INVOS System Presented at Annual Pediatric Academic Societies National Conference